Cosmos Health reports record revenue. Cosmos Health stock falls 3.45 percent

Published on 10/08/2026 at 20:25 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Preliminary revenue reached USD 54.30 million, up 19.00 percent year over year. Cosmos Health stock stood at EUR 0.28 on October 8, 2026 after EUR 0.29.

Key points in brief

Cosmos Health reported preliminary nine-month 2026 revenue of USD 54.30 million on October 7, 2026.
Preliminary third-quarter revenue reached USD 17.40 million, up 2.00 percent year over year.
Cana Laboratories' production pipeline exceeded 32.70 million units on September 28, 2026.
COSM was at EUR 0.28 at Lang & Schwarz on October 8, 2026, down 3.45 percent versus the prior close.

COSM, US2214133058, Illustration mit AI erstellt.

Cosmos Health reported preliminary nine-month revenue of USD 54.30 million on October 7, 2026, while Cosmos Health stock was trading at EUR 0.28 in after-hours trading on October 8, 2026, down 3.45 percent versus the prior close. StockTitan reported that the nine-month figure was preliminary and unaudited, with third-quarter revenue at USD 17.40 million and full-year 2026 revenue expected to surpass USD 90.00 million.

Revenue sets a higher base

The nine-month figure was USD 8.70 million above the USD 45.60 million reported for the same period of 2025, a year-over-year increase presented by the company as 19.00 percent. Third-quarter revenue rose from USD 17.10 million in the third quarter of 2025 to USD 17.40 million in the third quarter of 2026, an increase presented as 2.00 percent.

The outlook remains a forecast rather than a reported result. The company reaffirmed full-year 2026 revenue above USD 90.00 million and identified the fourth quarter as its strongest expected quarter, while the preliminary figures remain subject to quarter-end review.

Three milestones explain the buildout

On September 15, 2026, Cana Laboratories secured five-year Target Pharma agreements covering 5.20 million units. Yahoo Finance reported that the agreements lifted the orderbook above 32.70 million units, 31.00 percent above its June 2026 level.

On September 28, 2026, Cana's production pipeline exceeded 32.70 million units and carried implied lifetime revenue above USD 20.00 million. StockTitan said the implied revenue spans multi-year agreements and does not represent recognized revenue.

On October 7, 2026, the preliminary nine-month revenue update became the latest milestone. The sequence matters because the operating expansion is now visible in both the contract pipeline and the reported revenue run rate.

What does the revenue update change?

The new figures place USD 54.30 million of revenue in the first nine months, compared with USD 65.30 million for full-year 2025. That means the company had reached 83.26 percent of the prior year's full-year revenue before the final quarter, while the USD 90.00 million outlook implies a further step up from 2025.

Dates and stock context

MarketBeat lists November 13, 2026 as the estimated next earnings date. Its current rating table shows one Sell research rating and no Buy or Hold ratings, giving the revenue update a clear counterweight in the market narrative.

At Lang & Schwarz, COSM was trading at EUR 0.28 on October 8, 2026 at 8:15 p.m. CEST in after-hours trading, down 3.45 percent versus the prior close of EUR 0.29 on October 7, 2026. The primary listing is NASDAQ in USD, and the 52-week range was USD 0.16 to USD 1.32 as of October 8, 2026. The finance quote placed market capitalization at USD 16.9 million at the same date.

The further course of trading is shown by the continuously updated real-time quote of Cosmos Health stock.